ALG1 anticorps (N-Term)
Aperçu rapide pour ALG1 anticorps (N-Term) (ABIN635919)
Antigène
Voir toutes ALG1 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- N-Term
-
Specificité
- ALG1 antibody was raised against the N terminal of ALG1
-
Purification
- Affinity purified
-
Immunogène
- ALG1 antibody was raised using the N terminal of ALG1 corresponding to a region with amino acids VVLGDVGRSPRMQYHALSLAMHGFSVTLLGFCNSKPHDELLQNNRIQIVG
-
-
-
-
Indications d'application
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
ALG1 Blocking Peptide, (ABIN5612017), is also available for use as a blocking control in assays to test for specificity of this ALG1 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of ALG1 antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- ALG1 (Chitobiosyldiphosphodolichol beta-Mannosyltransferase (ALG1))
-
Autre désignation
- ALG1
-
Sujet
- ALG1 catalyzes the first mannosylation step in the biosynthesis of lipid-linked oligosaccharides. Defects in ALG1 are the cause of congenital disorder of glycosylation type 1K (CDG1K).
-
Poids moléculaire
- 52 kDa (MW of target protein)
Antigène
-